292 related articles for article (PubMed ID: 16722529)
1. Glanzmann thrombasthenia.
Nurden AT
Orphanet J Rare Dis; 2006 Apr; 1():10. PubMed ID: 16722529
[TBL] [Abstract][Full Text] [Related]
2. New Insights Into the Treatment of Glanzmann Thrombasthenia.
Poon MC; Di Minno G; d'Oiron R; Zotz R
Transfus Med Rev; 2016 Apr; 30(2):92-9. PubMed ID: 26968829
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of platelet surface glycoproteins in patients with Glanzmann thrombasthenia: Association with bleeding symptoms.
Mutreja D; Sharma RK; Purohit A; Aggarwal M; Saxena R
Indian J Med Res; 2017 May; 145(5):629-634. PubMed ID: 28948953
[TBL] [Abstract][Full Text] [Related]
4. Intensive menstrual bleeding successfully treated with recombinant factor VIIa in Glanzmann thrombasthenia.
Balci YI; Karabulut A; Kabukcu S; Sari I; Keskin A
Clin Appl Thromb Hemost; 2011 Aug; 17(4):320-2. PubMed ID: 20460355
[TBL] [Abstract][Full Text] [Related]
5. Glanzmann thrombasthenia: genetic basis and clinical correlates.
Botero JP; Lee K; Branchford BR; Bray PF; Freson K; Lambert MP; Luo M; Mohan S; Ross JE; Bergmeier W; Di Paola J;
Haematologica; 2020 Apr; 105(4):888-894. PubMed ID: 32139434
[TBL] [Abstract][Full Text] [Related]
6. First description of an IgM monoclonal antibody causing α
Pillois X; Guy A; Choquet É; James C; Tuffigo M; Viallard JF; Garcia C; Bordet JC; Jandrot-Perrus M; Payrastre B; Fiore M
J Thromb Haemost; 2019 May; 17(5):795-802. PubMed ID: 30868743
[TBL] [Abstract][Full Text] [Related]
7. Glanzmann thrombasthenia: an update.
Franchini M; Favaloro EJ; Lippi G
Clin Chim Acta; 2010 Jan; 411(1-2):1-6. PubMed ID: 19854165
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic expression of the platelet-specific integrin, alphaIIbbeta3, in a murine model for Glanzmann thrombasthenia.
Fang J; Hodivala-Dilke K; Johnson BD; Du LM; Hynes RO; White GC; Wilcox DA
Blood; 2005 Oct; 106(8):2671-9. PubMed ID: 15972454
[TBL] [Abstract][Full Text] [Related]
9. Successful management of perioperative hemostasis in a patient with Glanzmann thrombasthenia who underwent a right total mastectomy.
Ogawa Y; Kunishima S; Yanagisawa K; Osaki Y; Uchiyama Y; Matsumoto N; Tokiniwa H; Horiguchi J; Nojima Y; Handa H
Int J Hematol; 2017 Feb; 105(2):221-225. PubMed ID: 27696190
[TBL] [Abstract][Full Text] [Related]
10. Glanzmann's thrombasthenia (defective platelet integrin alphaIIb-beta3): proposals for management between evidence and open issues.
Di Minno G; Coppola A; Di Minno MN; Poon MC
Thromb Haemost; 2009 Dec; 102(6):1157-64. PubMed ID: 19967146
[TBL] [Abstract][Full Text] [Related]
11. A novel Pro126His beta propeller mutation in integrin alphaIIb causes Glanzmann thrombasthenia by impairing progression of pro-alphaIIbbeta3 from endoplasmic reticulum to Golgi.
Shen WZ; Ding QL; Jin PP; Wang XF; Jiang YZ; Li SM; Wang HL
Blood Cells Mol Dis; 2009; 42(1):44-50. PubMed ID: 18976939
[TBL] [Abstract][Full Text] [Related]
12. A rare case of bleeding disorder: Glanzmann's thrombasthenia.
Swathi J; Gowrishankar A; Jayakumar SA; Jain K
Ann Afr Med; 2017; 16(4):196-198. PubMed ID: 29063905
[TBL] [Abstract][Full Text] [Related]
13. Anti-α
Fiore M; d'Oiron R; Pillois X; Alessi MC
Br J Haematol; 2018 Apr; 181(2):173-182. PubMed ID: 29611179
[TBL] [Abstract][Full Text] [Related]
14. Control of severe bleeding episode in case of Glanzmann's thrombasthenia refractory to platelet transfusion therapy by administering recombinant factor VIIa.
Javed A; Ayyub M; Abrar S; Mansoor M; Khan B; Hussain T
J Ayub Med Coll Abbottabad; 2009; 21(2):171-3. PubMed ID: 20524499
[TBL] [Abstract][Full Text] [Related]
15. In silico analysis of structural modifications in and around the integrin αIIb genu caused by ITGA2B variants in human platelets with emphasis on Glanzmann thrombasthenia.
Pillois X; Peters P; Segers K; Nurden AT
Mol Genet Genomic Med; 2018 Mar; 6(2):249-260. PubMed ID: 29385657
[TBL] [Abstract][Full Text] [Related]
16. The international, prospective Glanzmann Thrombasthenia Registry: treatment and outcomes in surgical intervention.
Poon MC; d'Oiron R; Zotz RB; Bindslev N; Di Minno MN; Di Minno G;
Haematologica; 2015 Aug; 100(8):1038-44. PubMed ID: 26001792
[TBL] [Abstract][Full Text] [Related]
17. Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia.
Poon MC
Vasc Health Risk Manag; 2007; 3(5):655-64. PubMed ID: 18078017
[TBL] [Abstract][Full Text] [Related]
18. Characterisation of patients with Glanzmann thrombasthenia and identification of 17 novel mutations.
Sandrock-Lang K; Oldenburg J; Wiegering V; Halimeh S; Santoso S; Kurnik K; Fischer L; Tsakiris DA; Sigl-Kraetzig M; Brand B; Bührlen M; Kraetzer K; Deeg N; Hund M; Busse E; Kahle A; Zieger B
Thromb Haemost; 2015 Apr; 113(4):782-91. PubMed ID: 25373348
[TBL] [Abstract][Full Text] [Related]
19. Pyelolithotomy in a patient with Glanzmann thrombasthenia and antiglycoprotein IIb/IIIa antibodies: the shortest possible duration of treatment with recombinant activated factor VII and platelet transfusions.
Devecioğlu O; Unüvar A; Anak S; Bilge I; Ander H; Ziylan O
Turk J Pediatr; 2003; 45(1):64-6. PubMed ID: 12718376
[TBL] [Abstract][Full Text] [Related]
20. Bleeding and surgery in children with Glanzmann thrombasthenia with and without the use of recombinant factor VII a.
Hennewig U; Laws HJ; Eisert S; Göbel U
Klin Padiatr; 2005; 217(6):365-70. PubMed ID: 16307424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
